为期 9 年的研究发现，口腔喷雾疫苗 MV140 可预防 54% 的复发性尿路感染，且无明显副作用。 9-year study finds oral spray vaccine MV140 prevents 54% of recurrent UTIs with no significant side effects.
为期 9 年的研究表明，口腔喷雾剂疫苗 MV140 可以作为抗生素的潜在替代品，帮助超过一半的患者预防复发性尿路感染。 9-year study reveals an oral spray-based vaccine, MV140, as a potential alternative to antibiotics for preventing recurrent UTIs in more than half of patients. 研究的初步结果显示，54% 的参与者在接种疫苗后九年内没有出现尿路感染，并且没有报告任何明显的副作用。 Initial results from the study show that 54% of participants remained UTI-free for nine years after taking the vaccine, with no significant side effects reported. 预计完整结果将于 2024 年底公布。 The full results are expected to be published by the end of 2024.